These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20235351)

  • 1. [Erythropoesis-stimulating agents: past, present and future].
    Kes P; Basić-Jukić N
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():3-6. PubMed ID: 20235351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)].
    Lovcić V; Vujić J; Ivanac Janković R; Basić-Jukić N; Barisić I; Lovcić P; Dzapo M
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():11-6. PubMed ID: 20232547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anemia in chronic kidney disease and its cardiovascular implications].
    Cases A; Coll E; Collado S
    Med Clin (Barc); 2009 May; 132 Suppl 1():38-42. PubMed ID: 19460479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interaction between heart failure and other heart diseases, renal failure, and anemia.
    Silverberg DS; Wexler D; Iaina A; Schwartz D
    Semin Nephrol; 2006 Jul; 26(4):296-306. PubMed ID: 16949468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia in renal disease: diagnosis and management.
    Lankhorst CE; Wish JB
    Blood Rev; 2010 Jan; 24(1):39-47. PubMed ID: 19833421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anemia and cardiovascular risk in the patient with kidney disease.
    Fishbane S
    Heart Fail Clin; 2008 Oct; 4(4):401-10. PubMed ID: 18760752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of renal anemia in progression of chronic kidney disease].
    Racki S; Maleta I
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():33-7. PubMed ID: 20235353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anemia as a risk factor for CKD and CVD].
    Tsuruya K; Hirakata H
    Nihon Rinsho; 2008 Sep; 66(9):1786-93. PubMed ID: 18788410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management.
    Kanbay M; Perazella MA; Kasapoglu B; Koroglu M; Covic A
    Blood Purif; 2010; 29(1):1-12. PubMed ID: 19816014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characteristics of anaemia treatment in children with chronic kidney disease].
    Puretić Z
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():27-32. PubMed ID: 20235352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient.
    Schmid H; Schiffl H; Lederer SR
    Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):465-70. PubMed ID: 21738032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
    Doss S; Schiller B
    Nephrol Nurs J; 2010; 37(6):617-26. PubMed ID: 21290916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing anemia management in hospitalized patients with end-stage renal disease.
    Heung M; Mueller BA; Segal JH
    Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anemia treatment in peritoneal dialysis patients].
    Janković N; Janković M
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():17-22. PubMed ID: 20232548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic kidney disease-associated anemia: new remedies.
    Del Vecchio L; Cavalli A; Tucci B; Locatelli F
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1030-8. PubMed ID: 20730698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
    Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
    Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoiesis-stimulating agents: past and future.
    Nangaku M; Fliser D
    Kidney Int Suppl; 2007 Nov; (107):S1-3. PubMed ID: 17943137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of anemia in patients with chronic kidney disease.
    Wish JB
    Postgrad Med; 2004 Nov; 116(5 Suppl Anemia):23-9. PubMed ID: 19667681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.